This bill proposes to nullify specific modifications made by the Food and Drug Administration (FDA) in January 2023 to the risk evaluation and mitigation strategy (REMS) for the abortion pill mifepristone. The legislation directly voids these changes, aiming to restore the regulatory requirements for the drug to their previous state. Furthermore, the bill prohibits the Secretary of Health and Human Services, or any related department or agency, from establishing, implementing, or enforcing any provisions that are substantially similar to those nullified. This measure seeks to prevent future reintroduction of the specific regulatory adjustments made by the FDA concerning mifepristone's distribution and use.